EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New therapies for obesity

Dimitris Papamargaritis iD, Carel W le Roux iD, Jens J Holst iD, Melanie J Davies iD

Cardiovascular Research · 17.02.2024 · 119 (18) · 2825-2842

DOI: 10.1093/cvr/cvac176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 30.11.2022. Verfasst von Dimitris Papamargaritis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, Leicester General Hospital, University of Leicester College of Medicine Biological Sciences and Psychology, Leicester LE5 4…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leicester NIHR Biomedical Research Centre, National Institute of Clinical Research Clinical Lectureship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a chronic disease associated with serious complications and increased mortality. Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to compensatory biological adaptations (increased appetite and reduced energy expenditure) promoting weight gain. Bariatric surgery was until recently the only intervention that consistently resulted in ≥ 15% WL and maintenance. Our better understanding of the endocrine regulation of appetite has led to the development of new medications over the last decade for the treatment of obesity with main target the reduction of appetite. The efficacy of semaglutide 2.4 mg/week—the latest glucagon-like peptide-1 (GLP-1) receptor analogue—on WL for people with obesity suggests that we are entering a new era in obesity pharmacotherapy where ≥15% WL is feasible. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansObesityGlucagon-Like Peptide 1AppetiteWeight LossHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Bariatric surgeryLiraglutideObesityPharmacotherapySemaglutideTirzepatide

Substanzen

Glucagon-Like Peptide 1Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Diabetes Research Centre, Leicester General Hospital, University of Leicester College of Medicine Biological Sciences and Psychology, Leicester LE5 4PW, UK.
  • Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin 4, Ireland.
  • Diabetes Research Centre, Ulster University, Coleraine BT52 1SA, UK.
  • Department of Biomedical Sciences and the NNF Center for Basic Metabolic Research, University of Copenhagen Panum Institute, Copenhagen 2200, Denmark.

ORCID-Profile: Dimitris Papamargaritis, Carel W le Roux, Jens J Holst, Melanie J Davies

Förderung

  • Leicester NIHR Biomedical Research Centre
  • National Institute of Clinical Research Clinical Lectureship

Zitieren

APA

Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024). New therapies for obesity. Cardiovascular Research, 119(18), 2825-2842. https://doi.org/10.1093/cvr/cvac176

Vancouver

Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity. Cardiovascular Research. 2024;119(18):2825-2842. doi:10.1093/cvr/cvac176

BibTeX
@article{Papamargaritis2024,
  author = {Papamargaritis, Dimitris and le Roux, Carel W and Holst, Jens J and Davies, Melanie J},
  title = {New therapies for obesity},
  journal = {Cardiovascular Research},
  year = {2024},
  volume = {119},
  number = {18},
  pages = {2825--2842},
  doi = {10.1093/cvr/cvac176}
}
Kostenlos starten →